Yi-Chen Wu1, Ping Lv1, Jing Han1, Jiang-Liu Yu1, Xin Zhu1, Lian-Lian Hong1, Wang-Yu Zhu2, Qi-Ming Yu3, Xin-Bao Wang3, Pei Li4, Zhi-Qiang Ling1. 1. Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center No. 38 Guangji Rd., Banshanqiao District, Hangzhou 310022, P. R. China. 2. Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center No. 38 Guangji Rd., Banshanqiao District, Hangzhou 310022, P. R. China ; The Central Laboratory, Zhoushan Hospital Zhoushan 316000, P. R. China. 3. Department of Surgical Oncology, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center No. 38 Guangji Rd., Banshanqiao District, Hangzhou 310022, P. R. China. 4. Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University Zhengzhou 450052, China.
Abstract
OBJECTIVE: The present study is to evaluate the effect of methylated p16 on the progression in patients with gastric cancer (GC), and develop a useful biomarker for predicting patient's prognosis. DESIGN AND METHODS: Methylation status of p16 in GC, their corresponding para-cancerous histological normal tissues (PCHNTs), preoperative peritoneal washes (PPWs) and serum were assessed using real-time methylation specific-PCR (MSP). RESULTS: The frequency of p16 methylation was significantly higher in GC tissues (85.9%; 79/92) than that in paired PCHNTs (12.0%; 11/92) (P<0.0001). p16 methylation correlated closely with lymph node metastasis, peritoneal metastasis, TNM stage, et al (all P<0.05). Both frequency of p16 methylation in PPWs and serum were 79.7% (63/92). The Aζ value of the receiver-operator characteristic curve for methylated p16 was 0.899 for serum and PPWs, compared to that in GC tissues. The patients with elevated methylated p16 levels in tumor tissues had poorer disease-free survival (DFS) rates than those without (P=0.042). There is a narrow significant difference in median survival time of more than 30 months between patients with and without preoperatively detectable methylated p16 in serum (P=0.057). Methylated p16 in PPWs revealed no significant association with survival (P=0.129). Cox regression analysis showed that serum methylated p16 DNAs was an independent risk factor for GC patients, with a remarkable decrease in DFS 30 months after surgical resection of the gastric tumor. CONCLUSIONS: Serum methylated p16 DNAs might serve as a potential biomarker for the progression and a prognostic factor in gastric cancer patients.
OBJECTIVE: The present study is to evaluate the effect of methylated p16 on the progression in patients with gastric cancer (GC), and develop a useful biomarker for predicting patient's prognosis. DESIGN AND METHODS: Methylation status of p16 in GC, their corresponding para-cancerous histological normal tissues (PCHNTs), preoperative peritoneal washes (PPWs) and serum were assessed using real-time methylation specific-PCR (MSP). RESULTS: The frequency of p16 methylation was significantly higher in GC tissues (85.9%; 79/92) than that in paired PCHNTs (12.0%; 11/92) (P<0.0001). p16 methylation correlated closely with lymph node metastasis, peritoneal metastasis, TNM stage, et al (all P<0.05). Both frequency of p16 methylation in PPWs and serum were 79.7% (63/92). The Aζ value of the receiver-operator characteristic curve for methylated p16 was 0.899 for serum and PPWs, compared to that in GC tissues. The patients with elevated methylated p16 levels in tumor tissues had poorer disease-free survival (DFS) rates than those without (P=0.042). There is a narrow significant difference in median survival time of more than 30 months between patients with and without preoperatively detectable methylated p16 in serum (P=0.057). Methylated p16 in PPWs revealed no significant association with survival (P=0.129). Cox regression analysis showed that serum methylated p16 DNAs was an independent risk factor for GC patients, with a remarkable decrease in DFS 30 months after surgical resection of the gastric tumor. CONCLUSIONS: Serum methylated p16 DNAs might serve as a potential biomarker for the progression and a prognostic factor in gastric cancerpatients.
Authors: Thomas Luebke; Stephan E Baldus; Guido Grass; Elfriede Bollschweiler; Jürgen Thiele; Hans-Peter Dienes; Arnulf H Hoelscher; Stefan P Moenig Journal: World J Surg Date: 2005-11 Impact factor: 3.282
Authors: Hugo Sanchez; Mohammad B Hossain; Lydia Lera; Sandra Hirsch; Cecilia Albala; Ricardo Uauy; Karin Broberg; Ana M Ronco Journal: Clin Epigenetics Date: 2017-07-24 Impact factor: 6.551